Pharma channel feed

Up­dat­ed: Mer­ck KGaA con­tin­ues US tar­iff sur­charge but at a 'de­creased' rate 

Last month
China
Manufacturing

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

Last month
FDA+

Hen­grui, one of Chi­na's lead­ing biotechs, an­tic­i­pates $1.2B in pro­posed Hong Kong list­ing

Last month
Financing
China

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

Last month
FDA+

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

Last month
FDA+

Sanofi touts $20B in­vest­ment in US over five years

Last month
Manufacturing

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

Last month
FDA+

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

Last month
Startups
Deals

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

Last month
Deals

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

Last month
Deals

HHS fo­cus­es on 'trans­paren­cy' in third-round IRA ne­go­ti­a­tion guid­ance

Last month
Law

Some gener­ics, biosim­i­lar drug­mak­ers say they can with­stand tar­iff im­pact

Last month
Manufacturing

Watch Post-Hoc Live: Trump's 'most fa­vored na­tion' plan to cut drug prices

Last month

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

Last month
People

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Last month

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Last month
Law

PBM over­haul and drug price ne­go­ti­a­tions make the cut in Re­pub­li­can­s' tax bill

Last month
Law

Roche could re­think $50B US ex­pan­sion plan if new poli­cies 'har­m' op­er­a­tions

Last month
Manufacturing

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Last month

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

Last month
R&D

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

Last month
Manufacturing

Lon­za says its US-based sites are in high de­mand as phar­ma tar­iffs near

Last month
Manufacturing

Il­lu­mi­na con­firms SEC has closed in­ves­ti­ga­tion in­to $8B Grail deal

Last month
Diagnostics

Take­da an­nounces hand­ful of pipeline cuts in ef­fort to ‘piv­ot re­sources’

Last month
First page Previous page 2345678 Next page Last page
A service from the Financial Times